超声引导下射频消融治疗甲状腺微小乳头状癌术后吸收率的影响因素分析

doi:10.3969/j.issn.1006-7795.2023.06.006

摘要/Abstract

摘要： 目的探讨超声引导下射频消融（radiofrequency ablation，RFA)治疗甲状腺微小乳头状癌（papillary thyroid microcarcinoma，PTMC)的超声和病理特征对术后结节吸收率的影响。方法本研究对2020年12月至2022年3月期间进行超声引导下RFA治疗的PTMC患者进行了回顾性分析。术前收集患者的一般资料，并于术后第1、3、6、12、18个月进行随访，获得结节体积变化情况。以术后结节体积减小百分率（volume reduction ratio，VRR)达到100%的时间作为吸收率评估指标，采用单因素χ2检验及二元Logistic回归分析RFA术后结节吸收率的影响因素。结果本研究对56例接受RFA治疗的PTMC患者的64个结节进行了18个月的随访评估，术后1、3、6、12、18个月随访时结节的平均VRR为61.43%、 87.86%、96.62%、99.70%、100%。通过对吸收率相关因素分析发现，结节体积大于0.08 mL以及RFA时间大于130 s与患者术后吸收不良（达到100% VRR时间大于12个月)相关。Bethesda Ⅲ级的PTMC患者出现术后吸收不良的比例低于Bethesda Ⅴ/Ⅵ级患者。另外，PTMC患者伴有桥本甲状腺炎与术后低吸收率相关。二元Logistic回归分析显示RFA时长是RFA术后PTMC吸收率的独立影响因素。结论影响超声引导下RFA治疗PTMC术后吸收率的因素包括结节体积、RFA时长、Bethesda分级以及桥本甲状腺炎。RFA时长是RFA术后PTMC吸收率的独立影响因素。

关键词: 超声引导下射频消融, 甲状腺微小乳头状癌, Bethesda分级, 桥本甲状腺炎

Abstract: Objective To explore the ultrasound and pathological factors related to the absorption rate of ultrasound-guided radiofrequency ablation(RFA) in the treatment of papillary thyroid microcarcinoma (PTMC).Methods This study performed a retrospective analysis of patients with ultrasound-guided RFA for PTMC between December 2020 and March 2022. General information of patients was collected before RFA, and follow-up was performed at 1, 3, 6, 12 and 18 months after RFA to obtain changes in thyroid nodules volume. Taking the time when postoperative nodules reach 100% volume reduction ratio (VRR) as the absorption rate evaluation index, univariate χ2 test and Logistic regression were used to analyze the influencing factors of RFA treatment.Results A total of 64 TNs in 56 patients reached 100% VRR 18 months after RFA, the mean VRR of nodules at 1, 3, 6, 12, and 18 months after RFA were 61.43%, 87.86%, 96.62%, 99.70% and 100%.Through the analysis of ultrasound features, it was found that the nodule volume greater than 0.08 mL and the RFA time longer than 130 s were associated with low absorption rate (100% VRR time greater than 12 months). PTMC patients with Bethesda grade Ⅲ have a lower rate of absorption than patients with Bethesda class Ⅴ/Ⅵ. In addition, PTMC patients with Hashimoto's thyroiditis are associated with low absorption rate. Logistic regression analysis showed that RFA was independent influencing factors affecting the rate of absorption after RFA in PTMC patients. Conclusion Ultrasound features affecting the absorption rate of TNs by ultrasound-guided RFA include nodules volume,duration of RFA, Bethesda grade and Hashimoto's thyroiditis. RFA was independent factors of PTMC absorption rate after RFA.

Key words: ultrasound-guided radiofrequency ablation, papillary thyroid microcarcinoma, Bethesda grade, Hashimoto's thyroiditis

中图分类号:

R445

贾筱夏, 常莹, 侯文颖, 符颖, 张会单, 杨敬春. 超声引导下射频消融治疗甲状腺微小乳头状癌术后吸收率的影响因素分析[J]. 首都医科大学学报, 2023, 44(6): 941-947.

Jia Xiaoxia, Chang Ying, Hou Wenying, Fu Ying, Zhang Huidan, Yang Jingchun. nalysis of factors related to the absorption rate of papillary thyroid microcarcinoma after ultrasound-guided radiofrequency ablation[J]. Journal of Capital Medical University, 2023, 44(6): 941-947.

参考文献

［1］Tuttle R M, Li D, Ridouani F. Percutaneous ablation of low-risk papillary thyroid cancer［J］. Endocr Relat Cancer, 2023, 30(3): e220244.
［2］Haugen B R, Alexander E K, Bible K C, et al. 2015 American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American thyroid association guidelines task force on thyroid nodules and differentiated thyroid cancer［J］. Thyroid, 2016, 26(1): 1－133.
［3］Tuttle R M, Alzahrani A S. Risk stratification in differentiated thyroid cancer: from detection to final follow-up［J］. J Clin Endocrinol Metab, 2019, 104(9): 4087－4100.
［4］Chou R, Dana T, Haymart M, et al. Active surveillance versus thyroid surgery for differentiated thyroid cancer: a systematic review［J］. Thyroid, 2022, 32(4): 351－367.
［5］Hegedüs L, Miyauchi A, Tuttle R M. Nonsurgical thermal ablation of thyroid nodules: not if, but why, when, and how?［J］. Thyroid, 2020, 30(12):1691－1694.
［6］Min Y, Wang X, Chen H, et al. Thermal ablation for papillary thyroid microcarcinoma: how far we have come?［J］. Cancer Manag Res, 2020, 12:13369－13379.
［7］Tufano R P, Pace-Asciak P, Russell J O, et al. Update of radiofrequency ablation for treating benign and malignant thyroid nodules. the future is now［J］. Front Endocrinol (Lausanne), 2021, 12: 698689.
［8］Baldwin C K, Natter M B, Patel K N, et al. Minimally invasive techniques for the management of thyroid nodules［J］. Endocrinol Metab Clin North Am, 2022, 51(2): 323－349.
［9］Pace-Asciak P, Russell J O, Tufano R P. The treatment of thyroid cancer with radiofrequency ablation［J］. Tech Vasc Interv Radiol, 2022, 25(2): 100825.
［10］Chung S R, Suh C H, Baek J H, et al. Safety of radiofrequency ablation of benign thyroid nodules and recurrent thyroid cancers: a systematic review and meta-analysis［J］. Int J Hyperthermia, 2017, 33(8): 920－930.
［11］Muhammad H, Santhanam P, Russell J O. Radiofrequency ablation and thyroid nodules: updated systematic review［J］. Endocrine, 2021, 72(3): 619－632.
［12］Lim J Y, Kuo J H. Thyroid nodule radiofrequency ablation: complications and clinical follow up［J］. Tech Vasc Interv Radiol, 2022, 25(2): 100824.
［13］Yang Z, Yan L, Xiao J, et al. Long-term results of radiofrequency ablation for locally recurrent papillary thyroid carcinoma［J］. Int J Hyperthermia, 2023, 40(1): 2191912.
［14］Pak S J, Lee Y M, Kim P N, et al. Short-term outcome of adrenal radiofrequency ablation of adrenal cysts: a single-center experience［J］. Sci Rep, 2023, 13(1): 3267.
［15］Nguyen V B, Nguyen Thi X, Nguyen Van Vy H, et al. Radiofrequency versus ethanol ablation for single-session treatment of benign cystic thyroid nodules: a short-term retrospective study［J］. Ther Clin Risk Manag, 2023, 19: 97－104.
［16］Zhang C, Yin J, Hu C L, et al. Comparison of ultrasound guided percutaneous radiofrequency ablation and open thyroidectomy in the treatment of low-risk papillary thyroid microcarcinoma: a propensity score matching study［J］. Clin Hemorheol Microcirc, 2022, 80(2): 73－81.
［17］Kim J H, Baek J H, Lim H K, et al. 2017 thyroid radiofrequency ablation guideline: Korean society of thyroid radiology［J］. Korean J Radiol, 2018, 19(4): 632－655.
［18］Papini E, Monpeyssen H, Frasoldati A, et al. 2020 European thyroid association clinical practice guideline for the use of image-guided ablation in benign thyroid nodules［J］. Eur Thyroid J, 2020, 9(4): 172－185.
［19］Ha E J, Baek J H, Che Y, et al. Radiofrequency ablation of benign thyroid nodules: recommendations from the Asian conference on tumor ablation task force-secondary publication［J］. J Med Ultrasound, 2021, 29(2): 77－83.
［20］Mauri G, Hegedüs L, Bandula S, et al. European thyroid association and cardiovascular and interventional radiological society of Europe 2021 clinical practice guideline for the use of minimally invasive treatments in malignant thyroid lesions［J］. Eur Thyroid J, 2021, 10(3): 185－197.
［21］Wu L F, Zhou Y Y, Guan Y Y, et al. Washout DNA copy number analysis by low-coverage whole genome sequencing for assessment of thyroid FNAs［J］. Front Endocrinol (Lausanne), 2022, 13: 888072.
［22］Du J, Han R J, Chen C, et al. Diagnostic efficacy of ultrasound, cytology, and BRAFV600E mutation analysis and their combined use in thyroid nodule screening for papillary thyroid microcarcinoma［J］. Front Oncol, 2021, 11: 746776.
［23］Rosario P W, Mourão G F, Calsolari M R. Active surveillance in adults with low-risk papillary thyroid microcarcinomas: a prospective study［J］. Horm Metab Res, 2019, 51(11): 703－708.
［24］Gao Y, Qu N, Zhang L, et al. Preoperative ultrasonography and serum thyroid-stimulating hormone on predicting central lymph node metastasis in thyroid nodules as or suspicious for papillary thyroid microcarcinoma［J］. Tumour Biol, 2016, 37(6): 7453－7459.
［25］Zha X J, Miao Z C, Huang X, et al. The risk stratification of papillary thyroid cancer with Bethesda category Ⅲ (atypia of undetermined significance/follicular lesion of undetermined significance) by thyroid fine-needle aspiration could be assisted by tumor size for precision treatment［J］. Front Endocrinol (Lausanne), 2022, 13: 822423.
［26］Dobrinja C, Bernardi S, Fabris B, et al. Surgical and pathological changes after radiofrequency ablation of thyroid nodules［J］. Int J Endocrinol, 2015, 2015: 576576.
［27］Issa P P, Omar M, Issa C P, et al. Radiofrequency ablation of indeterminate thyroid nodules: the first North American comparative analysis［J］. Int J Mol Sci, 2022, 23(19): 11493.
［28］Caturegli P, De Remigis A, Rose N R. Hashimoto thyroiditis: clinical and diagnostic criteria［J］. Autoimmun Rev, 2014, 13(4/5): 391－397.
［29］Ieni A, Vita R, Magliolo E, et al. One-third of an Archivial series of papillary thyroid cancer (years 2007-2015) has coexistent chronic lymphocytic thyroiditis, which is associated with a more favorable tumor-node-metastasis staging［J］. Front Endocrinol (Lausanne), 2017, 8: 337.
［30］Resende de Paiva C, Grønhøj C, Feldt-Rasmussen U, et al. Association between Hashimoto's thyroiditis and thyroid cancer in 64,628 patients［J］. Front Oncol, 2017, 7: 53.
［31］Ralli M, Angeletti D, Fiore M, et al. Hashimoto's thyroiditis: an update on pathogenic mechanisms, diagnostic protocols, therapeutic strategies, and potential malignant transformation［J］. Autoimmun Rev, 2020, 19(10): 102649.
［32］Zheng H T, Xu J, Chu Y L, et al. A global regulatory network for dysregulated gene expression and abnormal metabolic signaling in immune cells in the microenvironment of graves' disease and Hashimoto's thyroiditis［J］. Front Immunol, 2022, 13: 879824.
［33］Zhang Y, Zhang M B, Luo Y K, et al. Effect of chronic lymphocytic thyroiditis on the efficacy and safety of ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma［J］. Cancer Med, 2019, 8(12): 5450－5458.
［34］Yan L, Liu Y, Li W H, et al. Long-term outcomes of ultrasound-guided thermal ablation for the treatment of solitary low-risk papillary thyroid microcarcinoma: a multicenter retrospective study［J］. Ann Surg, 2023, 277(5): 846－853.
［35］Lai L M, Liu Z H, Zhang J W, et al. Effect of Hashimoto's thyroiditis on the extent of the ablation zone in early stages of ultrasound-guided radiofrequency ablation for papillary thyroid microcarcinoma: a large cohort study of 772 patients［J］. Int J Hyperthermia, 2022, 39(1): 397－404.

[1]	宋海曼, 何文, 康睿君, 王立淑, 于腾飞, 张巍. 卵巢－附件影像报告和数据系统在卵巢肿瘤良恶性鉴别诊断中的应用价值[J]. 首都医科大学学报, 2023, 44(6): 948-952.
[2]	于腾飞, 殷露, 田道然, 宋海曼, 尹子毅, 张巍, 何文. 超微血流成像和彩色多谱勒血流显像在乳腺BI-RADS 4类微小结节中的临床应用[J]. 首都医科大学学报, 2023, 44(6): 921-927.
[3]	魏星月, 王连双, 王媛媛, 高孟泽, 何琼, 张瑶, 罗建文. 基于多模态超声成像数据的慢性肝病肝纤维化、炎症和脂肪变性的智能分级诊断[J]. 首都医科大学学报, 2023, 44(6): 928-935.
[4]	庄佳绵, 曾宇然, 陈绍琦. 高帧率剪切波评价血液透析患者冈上肌腱的力学性能[J]. 首都医科大学学报, 2023, 44(6): 936-940.
[5]	宋倩, 周倩, 孙宏, 李硕, 梅雪, 郭瑞君, 葛辉玉. Lindegaard指数预测早期脓毒症相关性脑病的临床价值[J]. 首都医科大学学报, 2023, 44(6): 959-965.
[6]	孙哲, 马姣姣, 张波. 胸膜超声在呼吸系统疾病中的应用现状及展望[J]. 首都医科大学学报, 2023, 44(6): 966-972.
[7]	宋海曼, 何文, 康睿君, 王立淑, 于腾飞, 张巍. 卵巢－附件影像报告和数据系统在卵巢肿瘤良恶性鉴别诊断中的应用价值[J]. 首都医科大学学报, 0, (): 948-952.
[8]	张姝, 王凯, 杨子皓, 乔真, 李晓桐, 袁磊磊, 艾林. ¹¹C-MET PET/CT筛查幕上较低级别胶质瘤IDH和1p/19q分子分型的应用价值[J]. 首都医科大学学报, 2022, 43(6): 826-833.
[9]	耿义强, 刘家金, 吴世娜, 孙树伟, 赵东, 宋敬斌, 孙亚兵, 王瑞民. NEMA NU 2-2018标准在PET/CT系统性能测试中的作用评价[J]. 首都医科大学学报, 2022, 43(6): 840-844.
[10]	徐洋, 王凯, 陈嫱, 艾林. 核医学分子影像在胶质瘤诊疗中的研究进展[J]. 首都医科大学学报, 2022, 43(6): 880-885.
[11]	黄黎香, 王绍舟, 曹宸, 夏爽. 豆纹动脉对基底节区脑组织定量灌注的影响及预后预测效果评价[J]. 首都医科大学学报, 2022, 43(1): 53-60.
[12]	王莉, 施昭, 孔祥, 杨柳, 刘亚, 罗松, 张龙江. 大脑前动脉A1段发育不良和分叉角度与前交通动脉瘤形成的相关性[J]. 首都医科大学学报, 2022, 43(1): 61-66.
[13]	张慧博, 杨晓旭, 刘欣圆, 顾华, 王双坤, 杨旗. 磁共振影像对脑静脉窦血栓形成的诊断价值研究[J]. 首都医科大学学报, 2022, 43(1): 67-73.
[14]	孙鹏慧, 李莹莹, 刘鑫, 贾学佳, 贾秀琴, 杨旗. 卒中相关性肺炎患者神经功能恶化的影像指标及其预测价值分析[J]. 首都医科大学学报, 2022, 43(1): 74-81.
[15]	康丽, 李硕, 熊颖, 郭瑞君. 托拉塞米联合葡萄糖快速利尿后超声技术诊断在役飞行员肾微小结石的临床价值[J]. 首都医科大学学报, 2021, 42(6): 1076-1080.